Annual Report and Accounts

The report describes BerGenBio's focused 2021 strategy for advancing bemcentinib in oncology and severe respiratory infections, with more than 600 patients treated to date. It also presents the company's expanded ESG program, including a materiality analysis, Board oversight of ESG, responsible sourcing, and explicit alignment with selected Sustainable Development Goals. The company began mapping its GHG emissions under the GHG Protocol and reported total 2021 emissions of 17,54 tonnes CO2e, primarily from business travel and purchased electricity and heat.